Rainbow Children's Medicare Ltd Announces Quarterly Financial Results and Key Leadership Appointment
Rainbow Children's Medicare Ltd has reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also announced a significant leadership transition following its Board meeting held on July 30, 2026.The Board of Directors approved the elevation of Mr. Anshuman Jaiswal from Group Head - Legal to Chief Legal Officer (CLO), designating him as a Senior Management Personnel (SMP) with immediate effect. Mr. Jaiswal is described as an India-qualified corporate counsel with over two decades of experience, having previously held roles at firms such as Amarchand Mangaldas and Cyril Amarchand Mangaldas.
Operational and Strategic Developments
The company reported several operational milestones in the period:- Hospital Expansion: The company executed definitive transaction documents concerning a proposed capacity addition through the development of a new children's and women's hospital at Malad, Mumbai, via its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited (RWCHPL). This transaction is expected to be completed in the quarter ended September 30, 2026.
- Acquisition: Subsequently, the company executed a Partnership Interest and Contribution Transfer Agreement (PICTA) with existing partners of Super Prime Medical Care LLP for the proposed acquisition of 64 percent partnership interest. The aggregate consideration for this acquisition is Rs 198 million, and the transaction is expected to be completed in the quarter ended September 30, 2026.
- Employee Stock Options: Under the Employee Stock Option Scheme 2025 (ESOP 2025), the Nomination and Remuneration Committee granted 267,550 stock options to eligible employees. These options are exercisable within a maximum of two years from the date of vesting and have a maximum vesting period of four years.
Financial Performance Highlights
The company reported its unaudited standalone results for the quarter ended June 30, 2026, as well as the unaudited consolidated financial results for the Group.Unaudited Standalone Financial Results (Qended June 30, 2026)
The following table details the key performance indicators from the standalone financials:| Particulars | Q Ended 30 June 2026 (Unaudited) | Ended 31 March 2026 (Audited) |
|---|---|---|
| Revenue from operations | 4,105.47 | 3,347.48 |
| Total income | 4,233.04 | 15,89.1.14 |
| Total expenses | 3,527.63 | 12,534.60 |
| Profit before tax / exceptional items | 705.41 | 3,356.54 |
| Profit after tax | 527.06 | 2,500.16 |
Unaudited Consolidated Financial Results (Qended June 30, 2026)
The Group reported the following figures for the quarter ended June 30, 2026:| Particulars | Q Ended 30 June 2026 (Unaudited) |
|---|---|
| Revenue from operations | 4,699.85 |
| Other income | 127.10 |
| Total income | 4,826.95 |
| Total expenses | 3,987.42 |
| Profit before tax | 839.53 |
| Profit after tax attributable to Owners of the Company | 625.40 |
The unaudited consolidated results include the financial performance of Rainbow Children's Medicare Limited and its subsidiaries, including Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, and Rainbow Women & Children's Hospital Private Limited, among others.
RAINBOW Stock Price Movement
Today, shares of Rainbow Childrens Medicare Limited gained 2.16%, closing at ₹1520.6 after a positive trading session. The stock saw robust activity as it traded for the day with a volume count reaching 134,389 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.